愛 帝 宮 母 嬰 健 康 股 份 有 限 公 司

AIDIGONG MATERNAL & CHILD HEALTH LIMITED

(Incorporated in Bermuda with limited liability)

(Stock code: 286)

(1) QUARTERLY UPDATE ON RESUMPTION PROGRESS; (2) LITIGATION UPDATES; (3) NON-COMPLIANCE WITH RULES 3.10(1), 3.10A, 3.21 AND 13.92(2) OF THE LISTING RULES; (4) UNAUTHORIZED CHANGE IN SHAREHOLDING STRUCTURE OF CERTAIN SUBSIDIARIES OF THE COMPANY; (5) RULE 6.01A(1) OF THE LISTING RULES; AND (6) CONTINUED SUSPENSION OF TRADING

This announcement is made by Aidigong Maternal & Child Health Limited (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09, 13.24A and 13.49(6) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited ("**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

References are made to the announcements of the Company dated 17 January, 5, 13, 18 March, 2, 30 April, 27 June, 20 August, 2 October, 20 November 2025, 26 January 2026, 20 February 2026, 20, 27 May 2026 and 4 August 2026 (collectively, the "**Announcements**") in relation to, among others, (i) the guidance for the resumption of trading in the Shares set by the Stock Exchange (the "**Resumption Guidance**"); (ii) quarterly updates on the resumption of trading of the shares of the Company; and (iii) the arbitration concerning the Alleged Entrustment Agreement. Unless otherwise defined or the context otherwise requires, capitalised terms in this announcement shall have the same meanings as those defined in the Announcements.

QUARTERLY UPDATE ON RESUMPTION PROGRESS

Business operations

The Group has continued business operations notwithstanding the suspension of trading in the Shares on the Stock Exchange.

In view of the limited cash balance of the Company, the Company has continued to explore opportunities to replenish its cash balance. However, as at the date of this announcement, the Company had not yet identified any feasible fundraising opportunities.

Update on the annual results and annual report for the year ended 31 December 2024 and 2025

As disclosed in the Announcements, the Company encountered difficulties in obtaining documents relating to Shenzhen Aidigong.

As at the date of this announcement, the Company has not yet received any financial information in relation to Shenzhen Aidigong, being the major subsidiary of the Company. As such, the Company may not determine the timetable for the publication of annual results and annual report for the year ended 31 December 2024 and 2025. Further announcements will be made by the Company as and when appropriate in the event of any expected dates of the publication of the annual results and annual report for the year ended 31 December 2024 and 2025 are determined.

Report of independent forensic investigator

Citylinkers Corporate Advisory Services Limited, an independent forensic accountant, has submitted a report (the "**Report**") to the IBC on the forensic investigation conducted against the Matters and other relevant allegations. The Report has been submitted to the Stock Exchange. As disclosed in the Report, the investigation has faced significant constraints as the investigation team could not have access to (i) the business operation venues; (ii) operating system; and (iii) recent financial information of Shenzhen Aidigong. Furthermore, the investigation team was unable to have direct communication with the relevant Board members at the material time, resulting in a lack of supporting evidence on the background of decision making and discussion process concerning certain key events. After reviewing the Report, the Board is of the view that there is not any finding in the Report that has not previously been disclosed by the Company.

LITIGATION UPDATES

Updates on Arbitration, Litigation, Shenzhen Aidigong Arbitration, Withdrawal of Litigation and Shenzhen Aidigong Litigation

As disclosed in the Announcements, the lawsuit concerning the validity of the Resolution and the Change of Legal Representative was heard in Shenzhen Futian People's Court on 23 March 2026 and up to this announcement, the Court has not yet issued a judgment.

Regarding to the arbitration, the Shenzhen Court of International Arbitration has issued a judgement in favour of the Guangdong Wanjia, the details of which have been set out in the announcement of the Company dated 4 August 2026. The Board is made aware that Ms. Zhu has applied to set aside the Arbitration judgement. Nevertheless, as at the date of this announcement, neither the Company nor Guangdong Wanjia has received any formal notice from any court in the PRC on the application to set aside the Arbitration judgement.

The Company will continue to seek legal advice in respect of the claims under the outstanding lawsuit above. As the outcome of the outstanding lawsuit is uncertain, the Group will make further announcements as and when appropriate in compliance with the Listing Rules.

NON-COMPLIANCE WITH RULES 3.10(1), 3.10A, 3.21 AND 13.92(2) OF THE LISTING RULES

As disclosed in the Announcements, as a result of the removal of the director of Mr. Chu Pui Ki Dickson and resignations of Ms. Meng and Mr. Wang, the composition of the Board comprises two executive Directors and one independent non-executive Director and hence the number of the independent non-executive Directors and the members of the Audit Committee has fallen below the minimum number required under the aforesaid Rules 3.10(1), 3.10A and 3.21 of the Listing Rules.

Pursuant to Rules 3.11 and 3.23 of the Listing Rules, the Company should appoint an additional independent non-executive director and a member of the Audit Committee within three months after failing to meet the requirements under Rules 3.10(1), 3.10A and 3.21 of the Listing Rules. The Company is in the process of identifying a suitable candidate for appointment as a new INED and filling the vacancy of a member of the Audit Committee. However, as at the date of this announcement, the Company has not yet complied with Rules 3.10(1), 3.10A and 3.21 of the Listing Rule.

Following the resignation of Ms. Meng as an executive director with effect from 20 January 2026, the Company has a single gender board of directors and in not compliance with Rule 13.92(2) of the Listing Rules. As at the date of this announcement, the Company has not yet complied the Rules 13.92(2) of the Listing Rule.

UNAUTHORIZED CHANGE IN THE SHAREHOLDNG STRUCTURE OF CERTAIN SUBSIDIARIES OF THE COMPANY

It has recently come to the attention of the Company that based on public information, there has been changes in the shareholding structure of certain subsidiaries of Shenzhen Aidigong between 24 July 2026 and 20 August 2026. Those changes took place shortly after the date of the Arbitration judgement, and the Board has grave concern on such changes.

The Company has never authorized such changes and has engaged legal expert to assess the legalities, effectiveness of such changes and the responsibilities of the relevant personnel.

RULE 6.01A(1) OF THE LISTING RULES

Under Rule 6.01A(1) of the Listing Rules, the Stock Exchange may cancel the listing of any securities that have been suspended from trading for a continuous period of 18 months. In the case of the Company, the 18-month period expires on 20 August 2026 (the "**Deadline**").

The Company has made an application to the Stock Exchange for an extension of the Deadline. The Company has not received any decision of the Stock Exchange as at the date of this announcement.

CONTINUED SUSPENSION OF TRADING

At the request of the Company, trading in the shares of the Company on the Stock Exchange has been suspended since 9:54 a.m. on 21 February 2025 and will remain suspended until further notice.

Shareholders and potential investors of the Company should exercise caution when dealing in the securities of the Company.

By Order of the Board
Aidigong Maternal & Child Health Limited
Huang Wenhua
Chairman and Executive Director

Hong Kong, 20 August 2026

As at the date of this announcement, the Board comprises Mr. Huang Wenhua and Mr. Li Runping as executive Directors; and Mr. Ma Siu Kit as independent non-executive Director.